Spotlight on Quotient Sciences’ drug product capabilities in Reading, UK – Part 1
Read moreAbout Quotient Sciences - Reading
In 2017, we acquired Pharmaterials, a CDMO based in Reading, UK. The acquisition strengthened and expanded our formulation and manufacturing capabilities and further supported the growth of our unique Translational Pharmaceutics® platform which continues to this day.
In 2022, Reading completed a £1.5 million expansion of its early development and manufacturing facility. This doubled our formulation development and analytical footprint at the facility, with increased office space also part of the expansion as continue to grow our team.
Today, Quotient Sciences - Reading is our drug product center of excellence with services including drug product development & manufacturing, HPAPI manufacturing up to PBLEC 4, psychedelics therapeutics drug product manufacturing, and clinical trial materials manufacturing to support the path to first-in-human clinical trials for orphan drugs for rare diseases, pediatrics, and more.
Meet our team
We help turn your molecules into medicines of the future, working as partners with a single goal of getting get new treatments to those in need, fast. Meet some of our team members who you'll see or work with when you have a project with us at Reading.
Martin Wing-King
Vice President & General Manager, Quotient Sciences - Reading
Martin Wing-King is Vice President & General Manager, Quotient Sciences - Reading. Martin joined Pharmaterials in 2008, a comp...
About Martin
Dr. Asma Patel
VP, Integrated Development Services
Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...
About Asma
Dr. Valeria Ciarnelli
Senior Director of Product Development
Dr. Valeria Ciarnelli is a Senior Director of Product Development at Quotient Sciences, with responsibility for scientific program...
About Valeria
